

NK2008

11th Meeting of the Society for Natural Immunity

Fremantle, Western Australia

26th – 30th October 2008


Proudly Supported by



THE UNIVERSITY OF
WESTERN AUSTRALIA

Achieving International Excellence

CSLTM



Abstract Book Sponsored by





The CSL Group has a combined heritage of outstanding contributions to medicine and human health with more than 90 years experience in the development and manufacture of vaccines and plasma protein biotherapies. Our strong commitment to funding research and development of protein based biological medicines for unmet medical needs underpins our continuing growth.



CSL Limited is a global, specialty biopharmaceutical company that researches, develops, manufactures and markets products to treat and prevent serious human medical conditions.

Headquartered in Melbourne Australia, the CSL Group includes CSL Bioplasma, CSL Biotherapies and ZLB Behring including ZLB Plasma Services. With major facilities in Australia, Germany, Switzerland and the United States, CSL has approximately 7500 employees working in 26 countries.

CSL's Head Office is located in Melbourne, at 45 Poplar Road, Parkville.
Please fax enquiries to 03 9389 1434 or access our Internet site at
www.csl.com.au

Welcome

Dear Colleagues

G'Day!

The Organizing Committee is delighted to welcome you all to Fremantle, Western Australia to participate in NK2008, the 11th Meeting of the Society for Natural Immunity.

Building on the success of ten previous meetings held in the United States and Europe, we hope NK2008 will provide numerous opportunities for professional networking, collaboration, discussion and debate around ***“new developments in NK cell biology and natural immunity”*** and how this impacts on critical biological functions including the ability to control infections and malignancies.

This is the first meeting of the Society for Natural Immunity to be held in the southern hemisphere, although Australians have been long-term active contributors to this field. Scientists in Perth have been involved in NK cell research for nearly 30 years with studies by Greg Bancroft and Geoff Shellam establishing a role for host genetic control of NK cell responses to murine cytomegalovirus. Thus, the meeting provides a unique and historical forum.

As always, this meeting will bring together international, national and local speakers to present cutting edge research. We thank our international invited speakers for their participation despite the long travel. Historically, these meetings have been the forum at which some of the most seminal findings in the field have been presented. Another key feature of these meetings is that they have been designed to facilitate interactions and the exchange and generation of new ideas. Lastly, the Society and its members have been strongly committed through various initiatives, including these meetings, to fostering the development of junior scientists. We trust that these fundamental commitments of the SNI and the NK cell meetings will be embraced by all participants.

We wish you a fruitful and successful meeting and a pleasant stay in Western Australia.

Our best wishes to all. The Organizers

Chris Andoniou

Jerome Coudert

Mariapia Degli-Esposti

Anthony Scalzo

Welcome

Dear colleagues,

On behalf of the Society for Natural Immunity, welcome to our 11th Annual Meeting and 23rd International Natural Killer Cell Workshop.

The organisers have set up an outstanding scientific programme, gathering experts to cover central topics in NK cell biology and attracting over 200 participants to Perth. We congratulate and are grateful to Mariapia, Tony, Jerome, and Chris for their endeavour. We also acknowledge all attendees for actively contributing to the scientific success of this event.

We will sadly miss Paul Leibson, a distinguished SNI member and good friend, who made seminal scientific contributions to the field. His memory was honoured at the SNI Symposium held during the last meeting of the American Association of Immunologists (San Diego 2000).

We encourage you to take the opportunity of enjoying both the scientific and social activities, and wish you a very pleasant stay in Perth. You are welcome to join the SNI and attend our next meeting organized by Stipan Jonjic in Dubrovnik, Croatia (April 2010).

With our warmest regards,

Miguel López-Botet

President

The Society for Natural Immunity

General Information

Registration Desk

Located in the Esplanade Hotel Fremantle Foyer

Opening Times:

Sunday	26 October	3.00pm - 6.00pm
Monday	27 October	7.30am - 5.30pm
Tuesday	28 October	8.00am - 4.30pm
Wednesday	29 October	8.00am - 5.00pm
Thursday	30 October	Closed

SECRETARIAT – PROFESSIONAL CONFERENCE ORGANISER

Debbie-Ann Scott or Emma Toovey
EECW Pty Ltd
12 Leura Street
Nedlands WA 6009
Telephone: (08) 9389 1488
Facsimile (08) (389 1499
www.eecw.com.au

Oral Presentations

Given the tight schedule we ask that you note the time allocation for your presentation and ensure you stay within this limit. We will have laptops running Windows XP loaded with PowerPoint2007. Technicians are available to load your presentation. Please provide your presentation to them in advance of your session.

Poster Presentations

Poster abstracts are arranged in alphabetical order, and each abstract has been assigned a number. Delegates can set up their posters in the Sirius Room on Monday 27th October during the Morning Tea Break and/or Lunch Break. Poster presenters should collect their posters on Wednesday 29th October no later than 2.15pm. All posters can stay up for the duration of this period.

There are two poster sessions:

Session 1: Monday 27th October 4.30pm – 5.30pm odd numbered abstracts
Session 2: Tuesday 28th October 6.30pm – 7.30pm even numbered abstracts

Posters are in portrait orientation, and should be no larger than 120 cm (height) x 90 cm (width).

Materials to affix your poster will be available from the registration desk.

General Information

Welcome Reception – Included in registration fee

The welcome reception will take place between 5.30pm and 7.30pm on Sunday the 26th October at the Resort Pool, Esplanade Hotel, Fremantle. Delegates will be able to catch up with colleagues while enjoying a drink and a barbeque meal.

Conference Dinner – Ticket only

The conference dinner will be held at the Observation Deck, Fraser's Restaurant, Kings Park Function Centre on Wednesday the 29th October. Coaches will collect delegates at 6.00pm from the Esplanade Hotel Fremantle and arrive at Kings Park at approximately 6.30pm. Delegates will have time to stroll the grounds and enjoy views of the city at dusk. Pre-dinner drinks will be served from 7.00pm at the Observation Deck. Buses will collect delegates at approximately 11.00pm for the return trip to the Esplanade Hotel.

NK by the Sea, day trip to Rottnest – Included in registration fee

The day trip at Rottnest Island is an informal day where you can chat with colleagues while spending some time at one of the island's many beaches or enjoying some of the islands other attractions. For some more information about Rottnest Island go to: <http://www.rottnestisland.com/en/default.htm>

Buses will collect delegates from the Esplanade Hotel at 9.30am on Thursday 30th October. The coach transfer to the Rottnest ferry terminal will take approximately 15 minutes, leaving plenty of time to board the chartered boat for a 10.00am departure

The return ferry from Rottnest Island will depart at 4.00pm, arriving in Northport, Fremantle at approximately 4.30pm, coaches will then transfer delegates to the Esplanade Hotel.

Should a delegate miss the 4.00pm charter, the last ferry leaves Rottnest at 4.30pm, and arrives in Fremantle at approximately 5.00pm, at the 'C Shed.' No bus charter will be available and delegates will need to make their own way back to the hotel which is approximately a 15 minute walk.

Travel Scholarships

The NK2008 scientific committee is pleased to announce the following delegates were awarded travel scholarships to the value of AU \$500. Congratulations to the winners.


Bélanger, S., McGill University, Montréal, Canada
Björkström, N., Karolinska Institute, Sweden
Brauner, H., Karolinska Institute, Sweden
Brodin, P., Karolinska Institute, Sweden
Burke, S., Babraham Institute, United Kingdom
Carlsten, M., Karolinska Institute, Sweden
Claus, M., University of Heidelberg, Germany
Gjertsen, N., University of South Florida, USA
Huntington, N., Pasteur Institute, France
Jafferji, I., University of Cambridge, United Kingdom
Kuttruff, S., University of Tübingen, Germany
Lakshmikanth, T., Karolinska Institute, Sweden
Magri, G., Universitat Pompeu Fabra (DCEXS), Spain
Mentlik, A., University of Pennsylvania, USA
Morvan, M., Université de Nantes, France
Rsales–Rivera, L., University of Guadalajara, Mexico
Sanborn, K., University of Pennsylvania, USA
Simhardi, V., University Hospital of Cologne, Germany
Van Den Broeck, T., Ghent University, Belgium

Sponsor Acknowledgements

Scientific meetings such as NK2008 cannot occur without the support of our trade partners.

The Organising committee would like to thank the following companies for their generous support of the NK2008 meeting.

Gold Sponsors



Silver Sponsors



Session Sponsors



Abstract Book Sponsor



Exhibitor



Support Sponsor



Sponsor Acknowledgements

The Organising committee would like to thank the following organisations for their generous support of the NK2008 meeting.



THE UNIVERSITY OF
WESTERN AUSTRALIA

Achieving International Excellence



Royal Perth
Hospital



Australasian Society for Immunology Incorporated

NK2008

Day By Day Program

Novo Nordisk seeks partnerships

to jointly develop therapies for chronic inflammatory and autoimmune disorders

Novo Nordisk is committed to developing treatments for inflammation, specifically psoriasis, rheumatoid arthritis, systemic lupus, inflammatory bowel disease, and multiple sclerosis.

Our partnering focus

We welcome protein and peptide opportunities at early discovery phase as well as clinical projects. We particularly focus on the following targets:


- Cell-surface molecules on NK and T cells
- Cytokines and chemokines.

Our inflammation pipeline contains fully human and humanized monoclonal antibodies approaching the clinic, including:

- Anti-IL-20, a fully human mAb
- Anti-C5aR, a humanized mAb
- Fully human and humanized mAb's targeting various NK-receptors.

We bring proteins from molecule to market

For 80 years we have discovered, developed and marketed protein-based products. In so doing, we leverage our world-class expertise in all aspects of expressing, engineering, formulating and delivering proteins.



Novo Nordisk is a worldwide market leader in diabetes and holds leading positions in: haemophilia with inhibitors, growth hormone disorders and hormone replacement therapy. We are headquartered in Denmark, employ 26,000 people, and have affiliates in 80 countries.

Read more at novonordisk.com/science/partnering



Programme

Sunday 26th October

3.00 PM - 6.00 PM Registration Desk Opens

5.30 PM - 7.30 PM Welcome Reception

Monday 27th October

Official Welcome

8.25 AM - 8.30 AM **Mariapia Degli-Esposti**

Session 1: Bice Perussia Lecture

8.30 AM - 9.10 AM **Marco Colonna**
A human NK cell subset provides an innate source of IL-22 for mucosal immunity

Session 2: Development & Education

Sponsored by



Chairs: **Hans-Gustaf Ljunggren & Werner Held**

9.15 AM - 9.35 AM **Wayne Yokoyama**
NK cell development and differentiation

9.35 AM - 9.50 AM **Inpyo Choi**
Roles of osteopontin in the development of natural killers from hematopoietic stem cells

9.50 AM - 10.05 AM **Nicholas Huntington**
Trans-presentation of IL-15 by IL-15R α promotes the development of human NK cells in vivo

10.05 AM - 10.20 AM **Andreas Diefenbach**
ROR γ t directs the differentiation program of IL-22-producing mucosal NK cells mediating epithelial homeostasis

10.20 AM - 10.35 AM **Claude Roth**
Mature B cells contain NK cell-specified precursors

10.35 AM - 11.05 AM **MORNING TEA**

Session 3: Infection

Sponsored by



Chairs: **Anthony French & Miguel López-Botet**

11.05 AM - 11.25 AM **Lewis Lanier**
NK cell-mediated recognition and response to mouse cytomegalovirus

11.25 AM - 11.40 AM **Gunasegaran Karupiah**
Resistance to poxvirus infection is mediated by multiple NKC-encoded NK cell receptors

11.40 AM - 11.55 AM **Edward Barker**
HIV Vpr induces natural killer cell killing of infected cells by induction of ULBP-1 and -2

11.55 AM - 12.10 PM **Michael Brown**
A genetic model for NK-mediated MCMV resistance in MA/My mice

12.10 PM - 12.25 PM **Christopher Andoniou**
NK cell control of adaptive anti-viral immunity

Programme

12.25 PM - 12.40 PM **Bojan Polić**
Altered NK Cell Development and Enhanced NK Cell-Mediated Resistance to MCMV in NKG2D-Deficient Mice

12.45 PM - 2.15 PM **LUNCH**

Session 4: Recognition & Activation

Chairs: **Jordan Orange & Andrew Makrigiannis**

2.15 PM - 2.35 PM **Angela Santoni**
The DNA damage response: A common pathway regulating the expression of different NK cell activating ligands on diseased cells

2.35 PM - 2.55 PM **Naoki Matsumoto**
Regulation of lung inflammation by KLRG1 on NK cells

2.55 PM - 3.10 PM **Erik Dissen**
KLRE/11 and KLRE/12: a novel pair of heterodimeric receptors that inversely regulate NK cell cytotoxicity

3.10 PM - 3.25 PM **Marianne Hokland**
Modulation of NK cells by therapeutic immunoglobulin formulation

3.25 PM - 3.40 pm **Koho Iizuka**
Essential role of the Ly49A stalk region for immunological synapse formation and signalling

3.40 PM - 4.00 PM **John Trowsdale**
KIR copy number variation

4.00 PM - 5.30 PM **Poster Viewing & Afternoon Tea**

Session 5: Clinical Applications

Sponsored by



Chairs: **Karl-Johan Malmberg & Campbell Witt**

5.30 PM - 5.50 PM **Andrea Velardi**
NK cell alloreactivity in experimental and clinical allogeneic haematopoietic transplantation

5.50 PM - 6.05 PM **Ashley Moffett**
Genetics and Biology of KIR/HLA-C interactions in human reproduction

6.05 PM - 6.20PM **Daniela Pende**
Anti-leukemia activity of alloreactive NK cells in haplo-HSCT: redefined role of activating and inhibitory KIR


6.20PM - 6.35 PM **Maike Smelt**
Cytomegalovirus infection promotes the destruction of islet allografts by enhancing proliferation and recruitment of Ly49s3 and Ly49i2-positive NK-cell subpopulations

6.35PM - 6.50 PM **Bree Foley**
New Rules for NK Alloreactivity Revealed by the CD107a-based Flow Cytometric Assay

6.50 PM - 7.10 PM **Jeffrey Miller**
Adoptive transfer of allogeneic NK cells in cancer and transplantation

7.10 PM - 7.30 PM **General Discussion: 'Unresolved Issues and Future Directions'**

The latest technological breakthrough is 800 million years old



Innate Pharma develops cutting-edge drug candidates that target the most archaic compartment of the immune system: innate immunity. First mover in this emerging field, Innate Pharma has three product platforms, targeting three classes of innate immunity receptors:

- TCR $\gamma\delta$ agonists
- NK receptors agonists and antagonists
- TLR agonists

The company's most advanced molecule is in Phase II clinical trials in cancer and viral infections. With its strong scientific position, its robust intellectual property portfolio and its R&D expertise, Innate Pharma opens the way to new therapeutic solutions in cancer, the primary focus of the company, as well as in infectious diseases and chronic inflammatory pathologies.

Programme

Tuesday 28th October

Session 6: Migration & Signalling

Chairs: **Eric Long & Marianne Hokland**

8.30 AM - 8.50 AM **Eric Vivier**

Differential roles of the transcription factor ROR γ t in the development of NKp46⁺ lymphoid-tissue inducer-like cells and NKp46⁺ natural killer cells in gut and skin

8.50 AM - 9.10 AM **Frances Brodsky**

A polymorphism in KIR affects immune function through alteration of receptor membrane traffic

9.10 AM - 9.30 AM **John Coligan**

Uncommon Trafficking Pathway of the CD94/NKG2A Inhibitory Receptor

9.30 AM - 9.50 AM **Sumati Rajagopalan**

Endosomal signaling for a pro-inflammatory NK cell response

9.50 AM - 10.10 AM **Ashley Mentlik**

Rapid granule coalescence to the MTOC is an early step in NK cell cytotoxicity and precedes polarization to the synapse

10.10 AM - 10.30 AM **William Kerr**

HLA and SHIP regulate the KIR repertoire in vivo

10.30 AM - 11.00 AM **MORNING TEA**

Session 7: Regulation & Interactions

Chairs: **James Carlyle & Deborah Burshtyn**

11.00 AM - 11.20 AM **Vinay Kumar**

Molecular Basis of the Dual Functions of 2B4 (CD244)

11.20 AM - 11.40 AM **Andrew Brooks**

The dual life of HLA-E: Recognition by both CD94-NKG2 receptors and the TCR

11.40 AM - 12.00 AM **Veronique Braud**

Central role for antigen-specific CD4⁺ T cells in the activation of NK cells in vivo

12.00 AM - 12.15 PM **Venkateswara Simhadri**

HLA-B-Associated-Transcript-3-Positive Exosomes Regulate Natural Killer Function in Innate and Adaptive Immune Responses

12.15 PM - 12.30 PM **Georges Leclercq**

Continuous CD27 triggering in vivo results in exhaustion of natural killer cells

12.30 PM - 12.45 PM **Hormas Ghadially**

NKp46 regulates T cell responses in vivo

12.45 PM - 1.05 PM **Werner Held**

Functional adaptation of NK cells to self-MHC Class I

1.05 PM - 2.30 PM **LUNCH**

Session 8: Development & Education 2

Chairs: **Wayne Yokoyama & Claude Roth**

2.30 PM - 2.50 PM **Klas Kärre**

Host MHC class I influence on frequencies as well as functions of subsets defined by inhibitory receptor expression: from "the at least one receptor" to the "rheostat" model

Programme

2.50 PM - 3.10 PM	Guido Ferlazzo <i>Functional and developmental relationships between human NK cell subsets</i>
3.10 PM - 3.25 PM	Ramit Mehr <i>Elucidating NK cell development in the bone marrow: combining experiments and mathematical modelling</i>
3.25 PM - 3.40 PM	Stephen Anderson <i>A KIR intronic promoter produces a spliced antisense transcript in human ES cells</i>
3.40 PM - 4.00 PM	Michael Caligiuri "Title to be confirmed"
4.00 PM - 4.30 PM	AFTERNOON TEA

Session 9: Cancer

Chairs:	Daniela Pende & Sarah Cooley
4.30 PM - 4.50 PM	Mark Smyth <i>NK cell receptors and tumour control</i>
4.50 PM - 5.05 PM	Stephan Gasser <i>Senescence selectively induces NKG2D ligand expression</i>
5.05 PM - 5.20 PM	Akira Shibuya <i>Accelerated Tumor Growth in Mice Deficient in DNAM-1 Receptor</i>
5.20 PM - 5.35 PM	Hollie Pegram <i>Gene Modified Natural Killer Cells for Cancer Immunotherapy</i>
5.35 PM - 5.50 PM	Shannon Burke <i>Natural killer cell recognition of mouse melanoma through DNAM-1 and NKp46</i>
5.50 PM - 6.05 PM	Jacques Deguine <i>Impact of NKG2D ligand expression on NK cell motility in solid tumors</i>
6.05 PM - 6.25 PM	Christina Bottino <i>Tumour immunosurveillance by NK cells</i>
6.30 PM - 7.30 PM	Poster Viewing & Refreshments



NOVARTIS

ONCOLOGY

Novartis Oncology is committed to developing novel and effective therapeutic strategies to improve patient care.

The Novartis Oncology pipeline includes a diverse array of developmental compounds – including cytotoxics, monoclonal antibodies and small molecules. In addition to our internal research efforts, Novartis Oncology is actively seeking strong research partnerships with:

- research scientists
- clinicians
- academic institutions
- biotechnology groups
- co-operative groups

for research collaborations in areas of mutual interest, including preclinical and translational projects and clinical trials.

For more information on the Novartis pipeline or to discuss possible collaborations please contact:

Dr Kerryn Loftus
Medical Director
Tel: (02) 9805 3555
E-mail: kerryn.loftus@novartis.com

Dr Sonia Yip
Senior Clinical Research Scientist
Preclinical & Translational Research Group
Tel: (02) 9805 3568
E-mail: sonia.yip@novartis.com

Novartis Pharmaceuticals Australia Pty Ltd
54 Waterloo Road, North Ryde, NSW 2113

www.novartis.com.au

Programme

Wednesday 29th October

Session 10: Recognition & Activation 2

Chairs:	Hilary Warren & Erhard Hofer
8.30 AM - 8.50 AM	Peter Parham <i>Recombination-mediated variation in the KIR3DL1/S1 NK-cell receptor</i>
8.50 AM - 9.10 AM	Cyril Fauriat <i>Minimal receptor requirements for induction of cytokine secretion by human resting NK cells</i>
9:10 AM - 9.25 AM	Tina Van Den Broeck <i>Ly49E-dependent inhibition of natural killer cells by urokinase plasminogen activator</i>
9.25 AM - 9.40 AM	Dale Godfrey <i>Functionally diverse NKT cell subsets have differential impact in regulation of Type 1 Diabetes in NOD mice.</i>
9.40 AM - 9.55 AM	Alan Baxter <i>Congenic Analysis of the NKT Cell Control Gene Nkt2 Implicates the Peroxisomal Protein Pxmp4</i>
9.55 AM - 10.10 AM	Todd Fehniger <i>Natural killer cell microRNA transcriptome defined by massively parallel sequencing</i>
10.10 AM - 10.30 AM	Eric Long <i>NK Cell Inhibition via Phosphorylation of the Adapter Crk</i>

10.30 AM - 11.00 AM **MORNING TEA**

Session 11: Dendritic Cells

Chairs:	Guido Ferlazzo & Marco Colonna
11.00 AM - 11.20 AM	Miguel López-Botet <i>NK cell response to human cytomegalovirus-infected dendritic cells</i>
11.20 AM - 11.40 AM	Diana Hansen <i>Role of NK cell-dendritic cell interactions in the induction of T cell responses involved in cerebral malaria</i>
11.40 AM - 11.55 AM	Daniel Andrews <i>IFN-γ dependent recruitment of mature CD27^{hi} NK cells to lymph nodes primed by dendritic cells</i>
11.55 AM - 12.10 PM	Kimberly Schluns <i>IL-15Rα+ Dendritic cells direct the in vivo development and maintenance of NK cells</i>
12.10 PM - 12.25 PM	Benedict Chambers <i>Activated plasmacytoid dendritic cells induce migration and activation of NK cells in vivo</i>
12.25 PM - 12.45 PM	Christian Munz <i>Human natural killer cell activation by dendritic cells during viral infection</i>

12.45 PM - 2.15 PM **LUNCH**

Programme

Session 12: Infection 2

Chairs:	Geoffrey Shellam & Mariapia Degli-Esposti
2.15 PM - 2.35 PM	Christine Biron <i>Activating receptors function in sustaining NK cell during viral infections</i>
2.35 PM - 3.55 PM	Tony Scalzo <i>Consequences of NKC and viral variation on mouse NK responsiveness</i>
2.55 PM - 3.15 PM	David Margulies <i>Structure, expression, and molecular interactions of mouse cytomegalovirus MHC-Iv molecules, m144, m152, and m153---insight into NK and T cell immunoevasion</i>
3.15 PM - 3.30 PM	Rebecca Aicheler <i>HCMV US11 suppresses cell surface expression of the NKG2D ligands MICA and MICB</i>
3.30 PM - 3.50 PM	Stipan Jonjić <i>The MCMV M04 protein plays a role in both the inhibition and activation of NK cells</i>
3.50 PM - 4.05 PM	General Discussion: 'Unresolved Issues and Future Directions'
4.05 PM - 4.20 PM	Close and Invitation to next meeting in Croatia by Stipan Jonjić

4.20 PM - 4.50 PM AFTERNOON TEA

6.00 PM	Bus Departs for Conference Dinner
6.30 PM - 7.00 PM	Pre-dinner stroll around Kings Park & Botanic Garden
7.00 PM	Conference Dinner

Thursday 30th October

NK by the Sea - Informal Discussions at Rottnest Island

9.30 AM - 5.00 PM	Buses collect delegates from Esplanade Hotel at 9.30 AM
	Boat leaves Fremantle at 10:00 AM - arrive Rottnest Island at 10:30 AM
	Boat leaves Rottnest at 4.00 PM - arrive Fremantle 4.30 PM
	Buses arrive Esplanade Hotel 5.00 PM

Delegate List

NAME	ORGANISATION	COUNTRY	EMAIL ADDRESS
Achour, A	Karolinska Institute	SWEDEN	adnane.achour@ki.se
Ainsworth, M	The University of Western Australia	AUSTRALIA	monique@lei.org.au
Anderson, S	SAIC-Frederick Inc, NCI	USA	andersn@ncifrf.gov
Andersson, S	Karolinska Institutet	SWEDEN	sandra.andersson.1@ki.se
Andoniou, C	Centre for Experimental Immunology	AUSTRALIA	candoniou@lei.org.au
Arps, V	Miltenyi Biotec GmbH	GERMANY	annabelk@miltenyibiotec.de
Baxter, A	Comparative Genomics Centre	AUSTRALIA	Alan.Baxter@jcu.edu.au
Baz Morelli, A	CSL Ltd	AUSTRALIA	adrianna.bazmorelli@csl.com.au
Beaton, R	Roche Products	AUSTRALIA	robyn.beaton@roche.com
Bélanger, S	Institut De Recherches Cliniques De Montreal	CANADA	simon.belanger@ircm.qc.ca
Beuneu, H	Institut Pasteur	FRANCE	hbeuneu@pasteur.fr
Bird, C	Monash University	AUSTRALIA	cathy.bird@med.monash.edu.au
Björkström, N	Karolinska Institutet	SWEDEN	niklas.bjorkstrom@ki.se
Bobrzynski, T	Medical University of Vienna	AUSTRIA	tomasz.bobrzynski@meduniwien.ac.at
Bouwer, A	University of Otago	NEW ZEALAND	bouan696@studentmail.otago.ac.nz
Braud, V	CNRS	FRANCE	braud@ipmc.cnrs.fr
Brodin, P	MTC	SWEDEN	petter.brodin@ki.se
Brooks, A	The University of Melbourne	AUSTRALIA	agbrooks@unimelb.edu.au
Brown, M	University of Virginia	USA	mgb4n@virginia.edu
Burke, S	Babraham Institute	UK	shannon.burke@bbsrc.ac.uk
Caligiuri, M	Ohio State University	USA	michael.caligiuri@osumc.edu
Carlsten, M	Karolinska Institutet	SWEDEN	mattias.carlsten@ki.se
Carlyle, J	University of Toronto	CANADA	james.carlyle@utoronto.ca
Catros, V	University of Rennes	FRANCE	veronique.catros@univ-rennes1.fr
Chambers, B	Karolinska Institute	SWEDEN	Benedict.Chambers@ki.se
Chan, W	St. Jude Children's Research Hospital	USA	Wing.Chan@stjude.org
Choi, I	KRIBB	KOREA	ipchoi@kribb.re.kr
Christiansen, F	PathWest Royal Perth Hospital	AUSTRALIA	Frank.Christiansen@health.wa.gov.au
Chung, A	The University of Melbourne	AUSTRALIA	awchung@unimelb.edu.au
Claus, M	University Heidelberg	GERMANY	maren.claus@immu.uni-heidelberg.de
Clements, C	Monash University	AUSTRALIA	craig.clements@med.monash.edu.au
Coligan, J	NIH/NIAID	USA	jooligan@niaid.nih.gov
Colonna, M	Washington University	USA	mcolonna@pathbox.wustl.edu
Cooley, S	University of Minnesota	USA	cool0023@umn.edu
Cooper, M	Washington University	USA	cooper_m@kids.wustl.edu
Coudert, J	Lions Eye Institute	AUSTRALIA	jerome@lei.org.au
Culley, F	Imperial College London	UK	f.culley@imperial.ac.uk
Degli-Esposti, M	Centre for Experimental Immunology	AUSTRALIA	maripia@cylene.uwa.edu.au
Deguine, J	Institut Pasteur	FRANCE	deguine@pasteur.fr
D'Ombain, M	The Walter & Eliza Hall Institute of Medical Research	AUSTRALIA	dombrain@wehi.edu.au
Edsparr, K	Department of Oncology	SWEDEN	karin.edsparr@oncology.gu.se
Fauriat, C	Kardinska Institute	SWEDEN	cfauriat@wanadoo.fr
Fehniger, T	Washington University	USA	tfehnige@wustl.edu
Fiserova, A	Institute of Microbiology, ASCR	CZECH REP.	fiserova@biomed.cas.cz
Foley, B	Royal Perth Hospital	AUSTRALIA	Bree.Foley@health.wa.gov.au
French, A	Washington University	USA	french_a@kids.wustl.edu
Galsgaard, E	Novo Nordisk A/S	DENMARK	edg@novonordisk.com
Gasser, S	National University of Singapore	SINGAPORE	micsg@nus.edu.sg
Ghadially, H	Lautenberg Center for General & Tumor Immunology	ISRAEL	homasg@hotmail.com
Gill, S	Stanford University	USA	saargill@stanford.edu
Gjertsen, N	University of South Florida	USA	nicole.gjertsen@moffitt.org
Godfrey, D	The University of Melbourne	AUSTRALIA	godfrey@unimelb.edu.au
Grell, S	Novo Nordisk A/S	DENMARK	sng@novonordisk.com
Hansen, D	The Walter & Eliza Hall Institute of Medical Research	AUSTRALIA	hansen@wehi.edu.au
Heatley, S	The University of Melbourne	AUSTRALIA	sheatley@arcbi.redcross.org.au
Held, W	Ludwig Institute for Cancer Research	SWITZERLAND	Werner.Held@lcr.unil.ch


Delegate List

NAME	ORGANISATION	COUNTRY	EMAIL ADDRESS
Heusel, J	University of Iowa	USA	jon-heusel@uiowa.edu
Hirayasu, K	The University of Tokyo	JAPAN	hirayasu-ky@umin.ac.jp
Hofer, E	Medical University of Vienna	AUSTRIA	erhard.hofer@meduniwien.ac.at renate.hofer- warbinek@meduniwien.ac.at
Hofer-Warbinek, R	Medical University of Vienna	AUSTRIA	warbinek@meduniwien.ac.at
Hokland, P	University Hospital of Aarhus	DENMARK	phokland@ki.au.dk
Hokland, M	University of Aarhus	DENMARK	mikrmh@mf.au.dk
Hsu, T	Chung Shan Medical University	TAIWAN	htc@csmu.edu.tw
Huntington, N	Pasteur Institute	FRANCE	nhunting@pasteur.fr
Huppert, V	Miltenyi Biotec GmbH	GERMANY	annabelk@miltenyibiotec.de
Iizuka, K	University of Minnesota	USA	iizuk001@umn.edu
Inngjerdinger, M	University of Oslo	NORWAY	marit.inngjerdinger@rr-research.no
Jafferji, I	University of Cambridge	UK	ij213@cam.ac.uk
Jaworowski, A	Bumet Institute	AUSTRALIA	anthonyj@bumet.edu.au
Jensen, T	Novo Nordisk A/S	DENMARK	TEUJ@Novonordisk.com
John, E	Royal Perth Hospital	AUSTRALIA	elisabeth.john@health.wa.gov.au
Jonjic, S	Faculty of Medicine University of Rijeka	CROATIA	jsipan@medri.hr
Kärre, K	Karolinska Institute	SWEDEN	klas.karre@ki.se
Karupiah, G	JCSMR, Australian National University	AUSTRALIA	Guna.Karupiah@anu.edu.au
Kastrukoff, L	University of British Columbia	CANADA	lomefk@interchange.ubc.ca
Koch, J	Institute of Biomedical Research	GERMANY	joachim.koch@em.uni-frankfurt.de
Koentgen, F	Ozgene	AUSTRALIA	ozgene@ozgene.com
Kmpotic, A	Faculty of Medicine University of Rijeka	CROATIA	astridk@medri.hr
Kuldova, M	Institute of Microbiology, ASCR	CZECH REP.	maky_k@seznam.cz
Kumar, V	University of Chicago	USA	vkumar@bsd.uchicago.edu
Kuppen, P	Leiden University Medical Center	NETHERLANDS	p.j.kuppen@lumc.nl
Kuttruff, S	University of Tübingen	GERMANY	sabrina.kuttruff@gmx.net
Kveberg, L	University of Oslo	NORWAY	lise.kveberg@rr-research.no
Lathbury, L	University of Western Australia	AUSTRALIA	louise.lathbury@health.wa.gov.au
Le Page, M	University of Western Australia	AUSTRALIA	michael.lepage@health.wa.gov.au
Lederoq, G	Ghent University	BELGIUM	georges.leclercq@ugent.be
Lee, S	Griffith University	AUSTRALIA	s.lee@griffith.edu.au
Lefringhausen, A	Miltenyi Biotec Australia	AUSTRALIA	astridl@miltenyibiotec.com.au
Lin, J	The University of Melbourne	AUSTRALIA	lin@unimelb.edu.au
Lion, E	Antwerp University	BELGIUM	eva.lion@ua.ac.be
Ljunggren, H	Center for Infectious Medicine	SWEDEN	hans-gustaf.ljunggren@ki.se
Long, E	Laboratory of Immunogenetics, NIAID, NIH	USA	eLong@nih.gov
Lopez-Botet, M	Universitat Pompeu Fabra	SPAIN	miguel.lopez-botet@upf.edu
Loske, C	Miltenyi Biotec GmbH	GERMANY	ClaudiaL@miltenyibiotec.de
Makrigiannis, A	Institut De Recherches Cliniques De Montreal	CANADA	andrew.makrigiannis@iroc.qc.ca
Malmberg, K	Karolinska Institute	SWEDEN	kalle.malmberg@ki.se
Mamessier, E	INSERM U891	FRANCE	emilie.mamessier@inserm.fr
Margulies, D	Laboratory of Immunogenetics, NIAID, NIH	USA	dhm@nih.gov
Matsumoto, N	The University of Tokyo	JAPAN	nmatsu@k.u-tokyo.ac.jp
McHugh, R	Miltenyi Biotec, Inc	USA	rmchugh@miltenyibiotec.com
Meehan, A	Monash University	AUSTRALIA	aislin.meehan@med.monash.edu.au
Mehr, R	Bar-Ilan University	ISRAEL	prof.ramit.mehr@gmail.com
Mentlik, A	University of Pennsylvania School of Medicine	USA	amentlik@mail.med.upenn.edu
Miller, J	University of Minnesota	USA	mille011@umn.edu
Moenedaey, G	Miltenyi Biotec GmbH	GERMANY	annabelk@miltenyibiotec.de
Moffett, A	University of Cambridge	UK	am485@cam.ac.uk
Morice, W	Mayo Clinic	USA	morice.william@mayo.edu
Morrison, M	Trinity College Dublin	IRELAND	morrison@tcd.ie
Morvan, M	ImmunoVirologie Et Polymorphisme Genetique	FRANCE	maelig.morvan@efs.sante.fr
Munz, C	University of Zurich	SWITZERLAND	munzcc@rockefeller.edu
Oei, V	National University Of Singapore	SINGAPORE	u0602903@nus.edu.sg
Orange, J	University of Pennsylvania School of Medicine	USA	orange@mail.med.upenn.edu

Delegate List

NAME	ORGANISATION	COUNTRY	EMAIL ADDRESS
Pegram, H	Peter MacCallum Cancer Centre	AUSTRALIA	hollie.pegram@petermac.org
Rajagopalan, S	Laboratory of Immunogenetics, NIAID, NIH	USA	sumi@nih.gov
Reiche, D	Medical University of Vienna	AUSTRIA	viktoria.Breinsberger@medunivien.ac.at
Retiere, C	EA 4271 ImmunoVirologie Et Polymorphisme Viral	FRANCE	christelle.retiere@efs.sante.fr
Robinson, J	Stemcell Technologies Inc	CANADA	julie.robinson@stemcell.com
Roth, C	Institut Pasteur	FRANCE	droth@pasteur.fr
Saez Borderias, A	Pompeu Fabra University	SPAIN	andreaena@gmail.com
Sanborn, K	University of Pennsylvania School of Medicine	USA	ksanborn@gmail.com
Sanos, S	Institute of Medical Microiology and Hygiene	GERMANY	stephanie.sanos@uniklinik-freiburg.de
Scalzo, A	Centre for Experimental Immunology	AUSTRALIA	scals@cylene.uwa.edu.au
Schmitz, J	Miltenyi Biotec GmbH	GERMANY	annabelk@miltenyibiotec.de
Schuster, I	Lions Eye Institute	AUSTRALIA	iona@lei.org.au
Seino, K	St. Marianna University School of Medicine	JAPAN	seino@marianna-u.ac.jp
Selathurai, A	Baker IDI Heart & Diabetes Institute	AUSTRALIA	ahrathy.selathurai@bakeridi.edu.au
Smelt, M	University Medical Center Groningen	NETHERLANDS	m.j.smelt@med.umcg.nl
Smyth, M	Peter MacCallum Cancer Centre	AUSTRALIA	mark.smyth@petermac.org
Soares Mendes, R	BD Biosciences	AUSTRALIA	Rosanna_soares_mendes@bd.com
Spee, P	Novo Nordisk A/S	DENMARK	spee@novonordisk.com
Steiner, N	Georgetown University	USA	steinern@georgetown.edu
Stoddart, P	Miltenyi Biotec Australia	AUSTRALIA	paulas@miltenyibiotec.com.au
Sullivan, L	The University of Melbourne	AUSTRALIA	lcsull@unimelb.edu.au
Svoboda, J	Institute of Microbiology, ASCR	CZECH REP.	svobac@yahoo.com
Tan, D	The University of Western Australia	AUSTRALIA	tand14@student.uwa.edu.au
Toutirais, O	University De Rennes	FRANCE	olivier.toutirais@chu-rennes.fr
Trotta, R	The Ohio State University	USA	rossana.trotta@osumc.edu
Trowsdale, J	University of Cambridge	UK	j233@cam.ac.uk
Turner, K		AUSTRALIA	kjtuner07@bigpond.com
Tzang, B	Chung Shan Medical University, Taichung, Taiwan	TAIWAN	bstzang@csmu.edu.tw
Van Bergen, J	LUMC	NETHERLANDS	J.van_Bergen@lumc.nl
Van Den Broeck, T	Ghent University	BELGIUM	t.vandenbroeck@ugent.be
Van Gelder, M	Academic Hospital Maastricht	NETHERLANDS	m.van.gelder@mumc.nl
Velardi, A	University of Perugia	ITALY	velardi@unipg.it
Vivier, E	CIML	FRANCE	beziers@ciml.univ-mrs.fr
Vonarbourg, C	Universität Freiburg	GERMANY	cedric.vonarbourg@uniklinik-freiburg.de
Walpole, N	Monash University	AUSTRALIA	nicholas.walpole@med.monash.edu.au
Wang, N	King's College London	UK	naiyin.2.wang@kcl.ac.uk
Warren, H	John Curtin School of Medical Research	AUSTRALIA	Hilary.Warren@anu.edu.au
Witt, C	Royal Perth Hospital	AUSTRALIA	campbell.witt@health.wa.gov.au
Wu, S	National Chung Cheng University	TAIWAN	biosfw@ccu.edu.tw
Yee, D	John Curtin School of Medical Research	AUSTRALIA	dean.yee@anu.edu.au
Yip, S	Novartis Pharmaceuticals Australia	AUSTRALIA	sonia.yip@novartis.com
Zhou, W	King's College London	UK	wuding.zhou@kcl.ac.uk
Zinkernagel, M	Lions Eye Institute	AUSTRALIA	martin@lei.org.au

Humanise the code...



humanise@ozgene.com

www.ozgene.com

Vector Design & Construction • KO, KI & Humanised Mice • Lentiviral tg Mice & Rats • Custom Breeding
The viral systems used by Ozgene Pty Ltd are used under license from Caltech - The California Institute of Technology and Tranzyme Inc.



Miltenyi Biotec

NK cell research

Discover our expertise!

- Isolation of NK cells and NK cell subsets
- NK cell phenotyping by flow cytometry
- Genotyping and mRNA expression profiling/KIR typing
- microRNA expression profiling

MACS® Products—innovative, comprehensive, reliable

Miltenyi Biotec GmbH
Friedrich-Ebert-Straße 68
51429 Bergisch Gladbach
Germany
Phone +49 2204 8306-0
Fax +49 2204 85197
macs@miltenyibiotec.de

Miltenyi Biotec Inc.
12740 Earhart Avenue
Auburn, CA 95602
USA
Phone 800 FOR MACS,
+1 530 888 8871
Fax +1 530 888 8925
macs@miltenyibiotec.com

**Miltenyi Biotec
Australia Pty. Ltd.**
Phone +61 02 8877 7400
macs@miltenyibiotec.com.au

Miltenyi Biotec B.V. (Benelux)
macs@miltenyibiotec.nl
Customer service Netherlands
Phone 0800 4020120
Customer service Belgium
Phone 0800 94016
Customer service Luxembourg
Phone 800 24971

**Miltenyi Biotec Trading
(Shanghai) Co., Ltd. (P.R. China)**
Phone +86 21 6235 1005
macs@miltenyibiotec.com.cn

Miltenyi Biotec SAS (France)
Phone +33 1 56 98 16 16
macs@miltenyibiotec.fr

Miltenyi Biotec S.r.l. (Italy)
Phone +39 051 646 0411
macs@miltenyibiotec.it

Miltenyi Biotec K.K. (Japan)
Phone +81 3 5646 8910
macs@miltenyibiotec.jp

**Miltenyi Biotec Asia Pacific
Pte. Ltd. (Singapore)**
Phone +65 6238 8183
macs@miltenyibiotec.com.sg

Miltenyi Biotec S.L. (Spain)
Phone +34 91 512 12 90
macs@miltenyibiotec.es

Miltenyi Biotec Ltd. (UK)
Phone +44 1483 799 800
macs@miltenyibiotec.co.uk

www.miltenyibiotec.com